Phuturdex › Diseases › Motor neuron disease
Drugs in development · updated 30 October 2026
Motor neuron disease: drugs in development
As of 30 October 2026 there are 10 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for motor neuron disease. 6 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| MasitinibMasitinib AB Science®, Alsitek® | III | 1 | NCT03127267 |
| Kamlanoflast | I–II | 1 | NCT07396818 |
| VHB937 | II | 1 | NCT06643481 |
| AMX0114 | I | 1 | NCT06665165 |
| NI112 | I | 1 | NCT07906665 |
| SNUG01 | Early I | 1 | NCT06645197 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| RiluzoleExservan®, Tiglutik Kit® | III | 2 | NCT03127267 |
| RanolazineAspruzyo Sprinkle®, Ranexa® | II | 1 | NCT06527222 |
| AcamprosateCampral® | I | 1 | NCT07204977 |
| DefinityPerfluoropropane | I | 1 | NCT07193953 |
Sorted by most advanced phase and number of active trials.
All 10 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Amyotrophic lateral sclerosis 79 drugs
- Spinal muscular atrophies 12 drugs
- Spinal Muscular Atrophies of Childhood 8 drugs
- Bulbo-Spinal Atrophy, X-Linked 8 drugs
- Multiple sclerosis 93 drugs
- Neuroinflammatory diseases 15 drugs
- Depression 73 drugs
- Neuromuscular manifestations 5 drugs
- Neuromuscular disease 14 drugs
- Muscular atrophy 5 drugs
- Frontotemporal dementia 11 drugs
- Chronic obstructive pulmonary disease 89 drugs
Broader categories
- Central nervous system disease 38 drugs
- Metabolic disease 30 drugs
- Nutritional and metabolic diseases 5 drugs
- Spinal cord disease 6 drugs
- Proteostasis Deficiencies 7 drugs
- Neurodegenerative Diseases 25 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D016472 “Motor Neuron Disease”.